FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2551736000> ?p ?o ?g. }

• W2551736000 endingPage "4721" @default.
• W2551736000 startingPage "4721" @default.
• W2551736000 abstract "Abstract Background: Multiple myeloma (MM) is characterised by the production of monoclonal immunoglobulin (Ig) and clonal proliferation of neoplastic plasma cells in bone marrow. The emergence of oligoclonal bands (OB) in serum and/or urine immunofixation electrophoresis (IFE) that is different to that observed at diagnosis has been reported with varying frequency in patients with stem cell transplantation (SCT) or favourable response to chemotherapy, although its prognostic relevance remains unclear. Here, we retrospectively analysed clinical records and results serial serum and/or urine IFE to determine the frequency, clinical characteristics and prognostic impact of OB that developed after treatment. We also analysed the effects of OB on the results of free light chain (FLC) assay that may affect the stringent CR (sCR) criteria proposed by the IMWG. Patients: We retrospectively reviewed 180 patients with MM admitted to the Department of Hematology/Oncology at Kameda Medical Center, Kamogawa, Japan, from January 2006 to May 2014.Seventeen patients were excluded from the analysis due to lack of appropriate follow-up data. Method: An OB was defined as the presence of a serum and/or urine IFE monoclonal spike that was different from the original myeloma protein in heavy and/or light chains, as well as a different IFE migration pattern. IFE was performed at least every three months after obtaining very good partial response (VGPR) and then until the disease progression or relapse was confirmed. Overall survival (OS) and progression free survival (PFS) were analyzed in 173 MM patients by the Kaplan–Meier method, and differences between the curves were calculated by two-sided log-rank test. Free light chain (FLC) and minimal residual disease measurement by multicolour flowcytometory (MFC) were performed to evaluate the response to treatment. Results: Myeloma response more than VGPR and CR were achieved in 87 (53.3%) and 54 (33.1%) patients, respectively. None of the patients with less than PR developed OB, and OB developed in 36.3% (12/33) and 51.9% (28/54) of the patients with VGPR and CR, respectively. Among the 30 patients who received SCT, 18 patients (60.0%) developed OB, whereas only 12 of 133 patients who did not receive SCT developed OB. The emergence of OB was significantly higher in patients receiving SCT (P < 0.001). The median PFS of the patients with and without OB were 79.4 months and 19.2 months (P = 0.028), respectively, and those of OS did not reached and 41.1 months (P < 0.001), respectively (Figure 1). However, if patient response was limited to CR, median PFS and OS of patients with and without OB were not significantly different between the two groups (79.4 months vs. 80.1months, respectively, P = 0.646; and not reached and not reached, respectively, P = 0.776; Figure 2). OB was observed in 60% of patients after SCT, and in 36.6% of patients more than VGPR without SCT (P<0.001). In the patients who received SCT, the presence of OB was not associated with either PFS or OS (20.0 months vs 44.7 months, P=0.543 and not reached vs not reached, P= 0.739, respectively; Figure3). We also analyzed the association between residual myeloma cells assessed by the MFC in the patients who achieved CR according to the development of OB. Although the patients with OB showed slightly lower levels of residual myeloma cells than those without OB (2.49 x10-4vs 4.15 x10-4), there was no significant difference between the two groups (P= 0.054). As the presence of OB may result in an abnormal serum FLC kappa/lambda ratio, we examined the association of FLC kappa/lambda ratio and development of OB in 28 patients who achieved CR. Abnormal FLC kappa/lambda ratio was observed in 10 (35.7%) and 4 (15.3%) patients with and without OB, respectively, among those with CR (P = 0.118). Conversely, OB was detected in 10 of the 14 patients with an abnormal FLC ratio (71.4%) versus 18 of 40 (45.0%) with a normal serum FLC ratio (P = 0.164) among those with CR. Conclusions: In conclusion, we showed that the emergence of OB occurred exclusively in patients with favourable myeloma responses (more than VGPR) and was associated with prolonged survival. Patients with OB appeared to have fewer residual myeloma cells compared to those without OB. However, its development did not confer an additional survival benefit among the patients who achieved CR. In addition, it is possible that the emergence of OB affects the sCR response criteria proposed by the IMWG. Figure 1 Figure 1. Figure 2 Figure 2. Figure 3 Figure 3. Disclosures No relevant conflicts of interest to declare." @default.
• W2551736000 created "2016-11-30" @default.
• W2551736000 creator A5010746455 @default.
• W2551736000 creator A5022626654 @default.
• W2551736000 creator A5025340212 @default.
• W2551736000 creator A5048163457 @default.
• W2551736000 creator A5049127192 @default.
• W2551736000 creator A5064026305 @default.
• W2551736000 creator A5067504416 @default.
• W2551736000 creator A5089203135 @default.
• W2551736000 date "2014-12-06" @default.
• W2551736000 modified "2023-09-29" @default.
• W2551736000 title "Prognostic Implications of Oligoclonal Bands in Patients with Multiple Myeloma:Its Development per Se did Not Confer the Prologation of Survival" @default.
• W2551736000 doi "https://doi.org/10.1182/blood.v124.21.4721.4721" @default.
• W2551736000 hasPublicationYear "2014" @default.
• W2551736000 type Work @default.
• W2551736000 sameAs 2551736000 @default.
• W2551736000 citedByCount "1" @default.
• W2551736000 countsByYear W25517360002021 @default.
• W2551736000 crossrefType "journal-article" @default.
• W2551736000 hasAuthorship W2551736000A5010746455 @default.
• W2551736000 hasAuthorship W2551736000A5022626654 @default.
• W2551736000 hasAuthorship W2551736000A5025340212 @default.
• W2551736000 hasAuthorship W2551736000A5048163457 @default.
• W2551736000 hasAuthorship W2551736000A5049127192 @default.
• W2551736000 hasAuthorship W2551736000A5064026305 @default.
• W2551736000 hasAuthorship W2551736000A5067504416 @default.
• W2551736000 hasAuthorship W2551736000A5089203135 @default.
• W2551736000 hasConcept C126322002 @default.
• W2551736000 hasConcept C141071460 @default.
• W2551736000 hasConcept C143998085 @default.
• W2551736000 hasConcept C159654299 @default.
• W2551736000 hasConcept C163864487 @default.
• W2551736000 hasConcept C194409129 @default.
• W2551736000 hasConcept C203014093 @default.
• W2551736000 hasConcept C2776364478 @default.
• W2551736000 hasConcept C2776694085 @default.
• W2551736000 hasConcept C2776855637 @default.
• W2551736000 hasConcept C2777250017 @default.
• W2551736000 hasConcept C2778808339 @default.
• W2551736000 hasConcept C2779050716 @default.
• W2551736000 hasConcept C2780007613 @default.
• W2551736000 hasConcept C2780026642 @default.
• W2551736000 hasConcept C2780739268 @default.
• W2551736000 hasConcept C2911091166 @default.
• W2551736000 hasConcept C36394416 @default.
• W2551736000 hasConcept C542903549 @default.
• W2551736000 hasConcept C71924100 @default.
• W2551736000 hasConcept C90924648 @default.
• W2551736000 hasConceptScore W2551736000C126322002 @default.
• W2551736000 hasConceptScore W2551736000C141071460 @default.
• W2551736000 hasConceptScore W2551736000C143998085 @default.
• W2551736000 hasConceptScore W2551736000C159654299 @default.
• W2551736000 hasConceptScore W2551736000C163864487 @default.
• W2551736000 hasConceptScore W2551736000C194409129 @default.
• W2551736000 hasConceptScore W2551736000C203014093 @default.
• W2551736000 hasConceptScore W2551736000C2776364478 @default.
• W2551736000 hasConceptScore W2551736000C2776694085 @default.
• W2551736000 hasConceptScore W2551736000C2776855637 @default.
• W2551736000 hasConceptScore W2551736000C2777250017 @default.
• W2551736000 hasConceptScore W2551736000C2778808339 @default.
• W2551736000 hasConceptScore W2551736000C2779050716 @default.
• W2551736000 hasConceptScore W2551736000C2780007613 @default.
• W2551736000 hasConceptScore W2551736000C2780026642 @default.
• W2551736000 hasConceptScore W2551736000C2780739268 @default.
• W2551736000 hasConceptScore W2551736000C2911091166 @default.
• W2551736000 hasConceptScore W2551736000C36394416 @default.
• W2551736000 hasConceptScore W2551736000C542903549 @default.
• W2551736000 hasConceptScore W2551736000C71924100 @default.
• W2551736000 hasConceptScore W2551736000C90924648 @default.
• W2551736000 hasIssue "21" @default.
• W2551736000 hasLocation W25517360001 @default.
• W2551736000 hasOpenAccess W2551736000 @default.
• W2551736000 hasPrimaryLocation W25517360001 @default.
• W2551736000 hasRelatedWork W119914118 @default.
• W2551736000 hasRelatedWork W1569435158 @default.
• W2551736000 hasRelatedWork W1988327297 @default.
• W2551736000 hasRelatedWork W1997787000 @default.
• W2551736000 hasRelatedWork W2047565570 @default.
• W2551736000 hasRelatedWork W2060630093 @default.
• W2551736000 hasRelatedWork W2151112811 @default.
• W2551736000 hasRelatedWork W2551736000 @default.
• W2551736000 hasRelatedWork W2610715546 @default.
• W2551736000 hasRelatedWork W4281651215 @default.
• W2551736000 hasVolume "124" @default.
• W2551736000 isParatext "false" @default.
• W2551736000 isRetracted "false" @default.
• W2551736000 magId "2551736000" @default.
• W2551736000 workType "article" @default.